Now showing items 1-10 of 33
How Did the 2003 Prescription Drug Re-Importation Bill Pass the House?
the major interest groups in the debate over allowing the re-importation of prescription drugs by utilizing a logit model and instrumental variables. Consistent with political support approach, the evidence suggests that ...
Effective Patent Life in Pharmaceuticals
(International Journal of Technology Management, 2000)
Economics of new oncology drug development.
(J Clin Oncol, 2007-01-10)
PURPOSE: Review existing studies and provide new results on the development, regulatory, and market aspects of new oncology drug development. METHODS: We utilized data from the US Food and Drug Administration (FDA), company ...
Encouraging the Development of New Vaccines
(Health Affairs, 2005)
The Ripple Effects of a Restrictive Medicaid Formulary (editorial)
(American Journal of Managed Care, 2003-10)
Increasing R&D incentives for neglected diseases: Lessons from the Orphan Drug Act
(International Public Goods And Transfer Of Technology Under A Globalized Intellectual Property Regime, 2005)
Distinguished economists, political scientists, and legal experts discuss the implications of the increasingly globalized protection of intellectual property rights for the ability of countries to provide their citizens ...
Generic Competition in the U.S. Pharmaceutical Industry
(International Journal of the Economics of Business, 2006-02)
How did the 2003 prescription drug re-importation bill pass the house?
(Economics and Politics, 2006-03-01)
We examine the major interest groups in the debate over allowing the re-importation of prescription drugs by utilizing a logit model and instrumental variables. Consistent with political support approach, the evidence suggests ...
Entry and competition in generic biologics
(Managerial and Decision Economics, 2007-06-01)
Patents for several blockbuster biological products are expected to expire soon. The Food and Drug Administration is examining whether biologies can and should be treated like pharmaceuticals with regard to generics. In ...
The Determinants of Pharmaceutical Research and Development Expenditures
(Journal of Evolutionary Economics, 2000)